The only worry I have is with Trump pushing HCQ and FDA being against it. If Camargo has FDA’s side and will see this thru nothing like it.
Considering the Mesoblast-Novartis deal last week was only for ARDS, IHL-675A has a wide range of applications to inflammation-linked diseases/ symptoms, I can only imagine how far are the pharma deals with or without FDA rubber stamping IHL-675A.
Below is just a glimpse of various diseases/ conditions which could benefit from our drug and hence the market/ deal potential.![]()
- Forums
- ASX - By Stock
- IHL
- Ann: Positive IHL-675A in vivo results and FDA Pathway
Ann: Positive IHL-675A in vivo results and FDA Pathway, page-61
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)